| Component: (Network and Table) | |
|---|---|
| Network | 107 - Statement - Consolidated Statements of Cash Flows (http://www.abiomed.com/taxonomy/role/StatementOfCashFlowsIndirect) |
| Table | Statement [Table] |
| Reporting Entity [Axis] | 0000815094 (http://www.sec.gov/CIK) |
| Legal Entity [Axis] | Entity [Domain] |
| Statement [Line Items] | Period [Axis] | ||
|---|---|---|---|
2011-04-01 - 2012-03-31 | 2010-04-01 - 2011-03-31 | 2009-04-01 - 2010-03-31 | |
Operating activities: | |||
Net income (loss) | 1,495,000 | (11,755,000) | (19,024,000) |
Adjustments required to reconcile net income (loss) to net cash provided by (used for) operating activities: | |||
Depreciation and amortization | 4,336,000 | 3,948,000 | 4,898,000 |
Bad debt expense | 117,000 | 139,000 | 22,000 |
Stock-based compensation | 7,773,000 | 5,421,000 | 5,365,000 |
Write-down of inventory | 1,833,000 | 2,781,000 | 3,536,000 |
Loss on disposal of fixed assets | 53,000 | 29,000 | 54,000 |
Deferred tax provision | 789,000 | 970,000 | 954,000 |
Change in unrealized loss on marketable securities | (342,000) | ||
Gain on sale of WorldHeart common stock | (456,000) | (6,389,000) | |
Gain on settlement of investment | (1,017,000) | ||
Changes in assets and liabilities: | |||
Accounts receivable | (5,284,000) | (1,923,000) | 2,210,000 |
Inventories | (6,229,000) | (1,508,000) | 927,000 |
Prepaid expenses and other assets | (239,000) | 161,000 | (560,000) |
Accounts payable | 287,000 | 2,480,000 | (1,387,000) |
Accrued expenses and other long-term liabilities | (1,330,000) | 605,000 | 2,299,000 |
Deferred revenue | 1,050,000 | 682,000 | 75,000 |
Net cash provided by (used for) operating activities | 3,634,000 | 1,574,000 | (7,362,000) |
Investing activities: | |||
Purchases of short-term marketable securities | (24,502,000) | (8,004,000) | (11,869,000) |
Proceeds from the sale and maturity of short-term marketable securities | 7,750,000 | 7,000,000 | 17,848,000 |
Proceeds from the sale of WorldHeart common stock | 456,000 | 6,389,000 | |
Proceeds from settlement of investment | 1,017,000 | ||
Contingent milestone payment on acquisition | (1,750,000) | ||
Expenditures for property and equipment | (1,745,000) | (1,804,000) | (1,800,000) |
Net cash (used for) provided by investing activities | (17,480,000) | (2,352,000) | 8,818,000 |
Financing activities: | |||
Proceeds from the exercise of stock options | 14,257,000 | 1,061,000 | 639,000 |
Proceeds from the issuance of stock under employee stock purchase plan | 423,000 | 313,000 | 340,000 |
Net cash provided by financing activities | 14,680,000 | 1,374,000 | 979,000 |
Effect of exchange rate changes on cash | (675,000) | 447,000 | 568,000 |
Net increase in cash and cash equivalents | 159,000 | 1,043,000 | 3,003,000 |
Cash and cash equivalents at beginning of year | 5,831,000 | 4,788,000 | 1,785,000 |
Cash and cash equivalents at end of year | 5,990,000 | 5,831,000 | 4,788,000 |
Supplemental disclosures: | |||
Fixed asset additions included in accounts payable | 535,000 | 48,000 | 107,000 |
Common shares issued for business acquisition | 3,827,000 | ||
Taxes paid, net of refunds | 300,000 | ||